|
|
1410 Commonwealth Dr. Suite 105
Wilmington, NC 28412 US
phone:910 332 6522
fax:
|
|
| Symbol |
private |
| Founded |
2010 |
| Employees |
7 |
|
|
| www.accugenomics.com
|
|
|
|
 |
| Summary Description |
| Gene expression tests for cancer diagnosis and treatment |
|
| Management |
| Nick Lazaridis, President; Manfred Frey, CFO |
| |
|
|
| |
|
| Keywords |
| gene expression tests, molecular diagnostics, lung cancer, cancer, nucleic acid, standardization, internal standards |
|
|
|
| Description |
|
AccuGenomics provides standardized, proprietary gene expression tests to accurately diagnose, monitor, and inform cancer treatment. The Company’s BCR-ABL molecular diagnostics test is intended for chronic myeloid leukemia patients previously diagnosed with a BCR-ABL MBCR fusion gene event, and monitors treatment efficiency, minimal residual disease, and follow-up for disease relapse. AccuGenomics’ lung cancer risk test (LCRT-AGx) 14 Gene Test identifies patients at highest genetic risk of lung cancer in order to prioritize them for CT screening, resulting in marked reduction of the annual cost of screening. This earlier-stage biotechnology company is also developing its nucleic acid qPCR (SNAQ) platform, which can standardize any quantitative multigene expression test and is ready to be applied in any therapeutic area. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members